| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 70.66 | 9.6% | 10.3% |
| Total Income | 70.66 | 9.6% | 10.3% |
| Expenditure | 76.90 | 4.9% | 23.4% |
| PBT | -10.65 | 156.9% | 34.8% |
| Net Profit | -11.03 | 156.0% | 39.7% |
| OPM | -8.83% | 5.38pp | 18.47pp |
| NPM | -15.61% | 40.82pp | 7.60pp |
| EPS | -0.09 | 156.3% | 40.0% |
BeautyHealth Reports Q3 2025: Revenue $70.7M, Adjusted EBITDA $8.9M
04 May 2026 · 4 May, 7:51 am
Summary
The Beauty Health Company announced its financial results for the third quarter ended September 30, 2025. Net sales were $70.7 million, a decrease of (10.3)% compared to the prior year period. Gross margin improved to 64.6% from 51.6% in Q3 2024. Adjusted EBITDA was $8.9 million, up from $8.1 million in the prior year. The company updated its fiscal year 2025 net sales guidance to $293 - $300 million and adjusted EBITDA to $37 - $39 million.
Key Highlights
- 1
Net sales were $70.7 million for the third quarter of 2025, a decrease of (10.3)% compared to Q3 2024.
- 2
Gross margin was 64.6% in Q3 2025, compared to 51.6% in Q3 2024, primarily due to lower inventory related charges and favorable mix shift towards consumable net sales.
- 3
Adjusted EBITDA was $8.9 million in Q3 2025, compared to $8.1 million in Q3 2024.
- 4
The company placed 875 delivery systems during Q3 2025, compared to 1,118 during Q3 2024.
- 5
Cash, cash equivalents, and restricted cash were approximately $219 million as of September 30, 2025, compared to approximately $370 million as of December 31, 2024.
- 6
Consumables net sales were $49.8 million for the third quarter of 2025.
- 7
The company updated its fiscal year 2025 net sales guidance to $293 - $300 million and adjusted EBITDA to $37 - $39 million.
Management Comments
Pedro Malha
"Our third-quarter results reflect disciplined execution and the continued strengthening of BeautyHealth’s foundation." "Revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeded the top end of our guidance range, supported by ongoing operational efficiency. While device sales remained under pressure, the recurring consumables business continued to demonstrate resilience and profitability. With a large installed base, a growing global community of providers, and a category-defining brand in Hydrafacial, we believe we have the right foundation to drive sustainable, profitable growth. The team remains focused on expanding the device footprint, growing consumables, strengthening commercial execution, and maintaining disciplined capital stewardship."
Informational and educational content only. Not investment advice.